Michael W Sill

Drop‐the‐Losers Design: Normal Case

Allan R Sampson, Michael W Sill, A. Sampson, 2005, Biometrical journal. Biometrische Zeitschrift.

Improved survival with bevacizumab in advanced cervical cancer.

Michael W Sill, Helen Huang, B. Monk, 2014, The New England journal of medicine.

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Michael W Sill, B. Monk, R. Burger, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.